Login
Login     |     Register     |     Recover Username/Password

Spiro Rombotis

Cyclacel Pharmaceuticals, Inc. (CYCC)

Spiro Rombotis is President and Chief Executive Officer of Cyclacel Pharmaceuticals, Inc. He joined the company in August 1997 and has 29 years of experience with pharmaceutical and biotechnology companies. He was previously Vice President of International Operations and Business Development; Managing Director, Europe; and Director, Japanese joint venture, at The Liposome Company, Inc. He also served as Vice President of Pharmaceuticals for Central and Eastern Europe and as Director of International Marketing at Bristol-Myers Squibb. He was Head of European Marketing and Sales, Head of Corporate Development and one of the first employees of Centocor, Inc., and worked in business development at Novartis AG. He holds a B.A. from Williams College and an MBA and a master's degree in hospital management, with honors, from the Kellogg School of Management at Northwestern University, where he serves on the Kellogg biotech advisory board. He also serves on the board of trustees of BioNJ, the biotechnology industry trade group in New Jersey.

Cyclacel Pharmaceuticals, Inc. (CYCC)
September 17, 2012 - Pharmaceuticals

TSWT - Subscribe now!

The Wall Street Transcript is a completely unique resource for investors and business researchers.

Over 20,000 CEO, Equity Analyst and Money Manager Interviews

TWST Newsletter

Weekly email with New In-Depth Interviews

Most Popular Interviews
Opportunities in Hepatitis C and Genomic Technologies
David Ferreiro

Published April 26, 2014 in Biotechnology and Pharmaceuticals

Buy ($75)
REITs Report Positive Earnings Driven by Occupancy Gains and Debt Reduction
John W. Guinee III

Published June 18, 2013 in REITs

Buy ($75)
Bullish Outlook for REITs as Interest Rates Remain Low
Alexander D. Goldfarb

"We cover 27 stocks ranging from apartments to student housing, shopping centers, malls, office, industrial and the net lease space.

TWST: When we spoke a year ago, you were bullish about the REIT space overall"

Published June 18, 2013 in REITs

Buy ($75)
Stronger Book Value for Mortgage REITs with Non-Agency Exposure
Douglas Harter

Published June 18, 2013 in REITs

Buy ($75)
Most Popular Reports
REITs

Published June 18, 2013

Topics Covered: Acquisition and Financing Costs - Pricing Power Outlook - Residential and Commercial REITs - Inexpensive Access to Capital - Apartment, Lodging, Self-Storage and Office REITs
Buy ($175)
Business and Application Software

Published June 7, 2013

Topics Covered: Application Software Consolidation Activity - Cloud Computing and SaaS Trends - Cloud Computing - SaaS and PaaS
Buy ($175)
Deep Value Investing

Published June 7, 2013

Topics Covered: Bottom-Up Stock Selection - Cyclical Sectors - Exposure to Emerging Markets - Large-Cap, Deep-Value - Value Oriented Strategy - High-Quality Companies - Value Investing - Deep Value
Buy ($175)
Top Company Interviews
  • MetLife, Inc.
  • Exxon Mobil Corp.
  • Stifel Financial Corp.
  • Estee Lauder Companies Inc.
  • Goldman Sachs Group Inc.
  • Seagate Technology
  • General Electric Co.
  • AT&T, Inc.
  • Wal-Mart Stores Inc.
  • Sprint Nextel Corp.
  • Intel Corporation